Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 192.14B | 198.20B | 175.39B | 161.29B | 136.74B |
Gross Profit | 51.60B | 50.80B | 57.38B | 55.65B | 50.59B |
EBITDA | 329.02M | 30.50B | 477.14M | 4.05B | 5.02B |
Net Income | -4.35B | 1.38B | 538.72M | 10.08B | 8.00B |
Balance Sheet | |||||
Total Assets | 796.53B | 808.39B | 823.15B | 806.28B | 767.72B |
Cash, Cash Equivalents and Short-Term Investments | 152.32B | 152.65B | 157.80B | 164.77B | 173.54B |
Total Debt | 241.86B | 233.57B | 228.36B | 257.87B | 250.87B |
Total Liabilities | 598.99B | 599.81B | 623.52B | 603.16B | 574.64B |
Stockholders Equity | 118.10B | 124.94B | 121.52B | 131.00B | 127.81B |
Cash Flow | |||||
Free Cash Flow | 15.61B | -3.35B | -5.45B | -9.64B | 2.73B |
Operating Cash Flow | 26.88B | 9.82B | 1.76B | -3.32B | 8.89B |
Investing Cash Flow | -126.97M | 17.59B | 35.58B | -536.96M | 612.52M |
Financing Cash Flow | -14.27B | -39.67B | -38.12B | -3.66B | 2.29B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $24.10B | 6.13 | 6.40% | 4.45% | -1.54% | 9.96% | |
75 Outperform | $41.44B | 7.47 | 4.95% | ― | ― | ||
72 Outperform | $338.32B | 5.36 | 7.93% | 5.16% | 8.48% | -1.70% | |
71 Outperform | $197.06B | 25.48 | 1.42% | 4.30% | 1.93% | -65.62% | |
67 Neutral | $86.88B | 73.87 | 0.47% | 4.94% | 6.44% | -95.37% | |
59 Neutral | AU$1.66B | 11.44 | -7.29% | 3.55% | 7.56% | 6.20% | |
57 Neutral | $45.21B | 44.05 | -3.59% | 0.36% | -4.89% | -404.51% |
Fosun International Limited has announced that its board of directors will hold a meeting on August 27, 2025, to approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting could have significant implications for the company’s financial strategy and shareholder returns, potentially affecting its market positioning and investor confidence.
Fosun International Limited announced a delay in the dispatch of a circular related to the deemed disposal of equity interest in Shanghai Yuyuan Jewelry Fashion Group Co., Ltd. The company has received a waiver from the Hong Kong Stock Exchange to extend the dispatch deadline to September 30, 2025, allowing more time to finalize the necessary information. This extension may impact stakeholders by providing additional time for the company to ensure comprehensive communication regarding the transaction.
Fosun International Limited announced a delay in the dispatch of a circular related to the deemed disposal of equity interest in Shanghai Yuyuan Jewelry Fashion Group. The company is seeking an extension from the Hong Kong Stock Exchange due to the need for additional time to finalize the circular’s information, impacting the timeline for shareholder communication.
Fosun International, through its subsidiary Henlius, has announced the proposed adoption of a Share Option Scheme and an RSU Scheme, which are subject to shareholder approval. These schemes aim to grant options and RSUs to participants, potentially reducing Fosun’s shareholding in Henlius from 63.43% to 58.73%, constituting a discloseable transaction under the Hong Kong Listing Rules.
Fosun International Limited has announced the grant of 49,530,000 share options to 154 directors and employees as part of its 2023 Option Scheme. This move aims to incentivize and retain key management and staff, potentially enhancing the company’s performance and competitiveness in its diverse sectors.
Fosun International Limited has appointed Mr. Luo Yuanli as a non-executive director, effective June 16, 2025. Mr. Luo, currently with Zhongrong Life Insurance, brings experience in management and compliance, and his appointment is expected to enhance the board’s diversity. This strategic move reflects Fosun’s commitment to strengthening its leadership team and potentially improving its governance and operational oversight.
Fosun International Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The announcement also details the roles and functions of each director within various board committees, highlighting the company’s governance structure.
Fosun International’s subsidiary, Yuyuan, is facilitating a capital increase for its Jewelry Fashion Group, aiming to raise up to RMB2 billion from no more than 40 investors. This strategic move involves a series of transactions that will result in a deemed disposal of equity interest, reducing Fosun’s indirect holding in the group to 91.03%. The transaction is classified as a major one under Hong Kong’s Listing Rules, necessitating shareholder approval and adherence to reporting requirements.
Fosun International Limited has outlined the terms of reference for its Nomination Committee, which is tasked with reviewing the board’s structure, size, and diversity, as well as recommending changes to align with the company’s corporate strategy. This move is aimed at enhancing governance and ensuring the board’s composition supports the company’s strategic goals, potentially impacting its operational efficiency and stakeholder confidence.
Fosun International Limited held its Annual General Meeting on June 5, 2025, where all proposed resolutions were passed with significant support. Key resolutions included the approval of financial statements, the declaration of a final dividend, the re-election of directors, and the authorization for share repurchase and issuance mandates. These decisions reflect the company’s strategic focus on maintaining strong governance and enhancing shareholder value.
Fosun International Limited has announced a supplemental agreement to the Sale and Purchase Agreement concerning the disposal of equity interest in Guangzhou Taotall Technology Co., Ltd. to Hangzhou Tianyuan Pet Products Co., Ltd. The supplemental agreement amends the terms of the original agreement, with the appraised value of Guangzhou Taotall set at RMB777 million. The transaction is contingent upon approvals from the shareholders and boards of both companies, as well as regulatory bodies.